Ambrilia Biopharma Inc announced that it has succeeded in manufacturing a final one-month formulation of goserelin intended for the treatment of prostate cancer and several gynaecological indications. The company has already developed a proprietary, novel three-month formulation of goserelin for which a phase-I/II clinical programme in prostate cancer patients was initiated in July 2008.
The details can be read here.
No comments:
Post a Comment